Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma
- 15 September 2000
- journal article
- review article
- Published by Elsevier in Immunology Letters
- Vol. 74 (1), 67-74
- https://doi.org/10.1016/s0165-2478(00)00251-0
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.The Journal of Experimental Medicine, 1996
- Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.The Journal of Experimental Medicine, 1996
- Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.The Journal of Experimental Medicine, 1996
- Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2JNCI Journal of the National Cancer Institute, 1994
- Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.The Journal of Experimental Medicine, 1994
- Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma VaccineAnnals of Surgery, 1992
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Abrogation of metastatic properties of tumour cells by de novo expression of H–2K antigens following H–2 gene transfectionNature, 1985
- Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformationNature, 1984
- Multiple tumour-specific antigens expressed on a single tumour cellNature, 1983